Literature DB >> 29654057

Platelets expressing IgG receptor FcγRIIA/CD32A determine the severity of experimental anaphylaxis.

Héloïse Beutier1,2,3, Béatrice Hechler4, Ophélie Godon1,2, Yu Wang1,2,5, Caitlin M Gillis1,2,3, Luc de Chaisemartin6,7, Aurélie Gouel-Chéron1,2,8, Stéphanie Magnenat4, Lynn E Macdonald9, Andrew J Murphy9, Sylvie Chollet-Martin6,7, Dan Longrois8,10, Christian Gachet4, Pierre Bruhns11,2, Friederike Jönsson11,2.   

Abstract

Platelets are key regulators of vascular integrity; however, their role in anaphylaxis, a life-threatening systemic allergic reaction characterized by the loss of vascular integrity and vascular leakage, remains unknown. Anaphylaxis is a consequence of inappropriate cellular responses triggered by antibodies to generally harmless antigens, resulting in a massive mediator release and rapidly occurring organ dysfunction. Human platelets express receptors for immunoglobulin G (IgG) antibodies and can release potent mediators, yet their contribution to anaphylaxis has not been previously addressed in mouse models, probably because mice do not express IgG receptors on platelets. We investigated the contribution of platelets to IgG-dependent anaphylaxis in human IgG receptor-expressing mouse models and a cohort of patients suffering from drug-induced anaphylaxis. Platelet counts dropped immediately and markedly upon anaphylaxis induction only when they expressed the human IgG receptor FcγRIIA/CD32A. Platelet depletion attenuated anaphylaxis, whereas thrombocythemia substantially worsened its severity. FcγRIIA-expressing platelets were directly activated by IgG immune complexes in vivo and were sufficient to restore susceptibility to anaphylaxis in resistant mice. Serotonin released by activated platelets contributed to anaphylaxis severity. Data from a cohort of patients suffering from drug-induced anaphylaxis indicated that platelet activation was associated with anaphylaxis severity and was accompanied by a reduction in circulating platelet numbers. Our findings identify platelets as critical players in IgG-dependent anaphylaxis and provide a rationale for the design of platelet-targeting strategies to attenuate the severity of anaphylactic reactions.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29654057     DOI: 10.1126/sciimmunol.aan5997

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  25 in total

1.  Platelets Disseminate Extracellular Vesicles in Lymph in Rheumatoid Arthritis.

Authors:  Nicolas Tessandier; Imene Melki; Nathalie Cloutier; Isabelle Allaeys; Adam Miszta; Sisareuth Tan; Andreea Milasan; Sara Michel; Abderrahim Benmoussa; Tania Lévesque; Francine Côté; Steven E McKenzie; Caroline Gilbert; Patrick Provost; Alain R Brisson; Alisa S Wolberg; Paul R Fortin; Catherine Martel; Éric Boilard
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-02-27       Impact factor: 8.311

2.  The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.

Authors:  Bianca Balbino; Pauline Herviou; Ophélie Godon; Julien Stackowicz; Odile Richard-Le Goff; Bruno Iannascoli; Delphine Sterlin; Sébastien Brûlé; Gael A Millot; Faith M Harris; Vera A Voronina; Kari C Nadeau; Lynn E Macdonald; Andrew J Murphy; Pierre Bruhns; Laurent L Reber
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

3.  Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018.

Authors:  Rachel L Miller; Maria Shtessel; Lacey B Robinson; Aleena Banerji
Journal:  J Allergy Clin Immunol       Date:  2019-06-24       Impact factor: 10.793

Review 4.  [What should specialist in internal medicine be aware of in patients treated with biologics? : Infections and autoimmune phenomena].

Authors:  Thomas Zander; Michael Hallek
Journal:  Internist (Berl)       Date:  2022-01-28       Impact factor: 0.743

5.  PEG: Will It Come Back to You? Polyethelyne Glycol Immunogenicity, COVID Vaccines, and the Case for New PEG Derivatives and Alternatives.

Authors:  Yi Wen Kong; Erik C Dreaden
Journal:  Front Bioeng Biotechnol       Date:  2022-04-27

6.  Blocking the inhibitory receptor programmed cell death 1 prevents allergic immune response and anaphylaxis in mice.

Authors:  Jyoti K Lama; Koji Iijima; Takao Kobayashi; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2022-01-29       Impact factor: 14.290

7.  FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus.

Authors:  Imene Melki; Isabelle Allaeys; Nicolas Tessandier; Benoit Mailhot; Nathalie Cloutier; Robert A Campbell; Jesse W Rowley; David Salem; Anne Zufferey; Audrée Laroche; Tania Lévesque; Natalie Patey; Joyce Rauch; Christian Lood; Arnaud Droit; Steven E McKenzie; Kellie R Machlus; Matthew T Rondina; Steve Lacroix; Paul R Fortin; Eric Boilard
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

8.  Apoptosis signal-regulating kinase 1 regulates immune-mediated thrombocytopenia, thrombosis, and systemic shock.

Authors:  Pravin Patel; Noor F Shaik; Yuhang Zhou; Kalyan Golla; Steven E McKenzie; Ulhas P Naik
Journal:  J Thromb Haemost       Date:  2020-09-09       Impact factor: 5.824

Review 9.  Roadmap and strategy for overcoming infusion reactions to nanomedicines.

Authors:  Janos Szebeni; Dmitri Simberg; África González-Fernández; Yechezkel Barenholz; Marina A Dobrovolskaia
Journal:  Nat Nanotechnol       Date:  2018-10-22       Impact factor: 39.213

10.  Complement activation on endothelium initiates antibody-mediated acute lung injury.

Authors:  Simon J Cleary; Nicholas Kwaan; Jennifer J Tian; Daniel R Calabrese; Beñat Mallavia; Mélia Magnen; John R Greenland; Anatoly Urisman; Jonathan P Singer; Steven R Hays; Jasleen Kukreja; Ariel M Hay; Heather L Howie; Pearl Toy; Clifford A Lowell; Craig N Morrell; James C Zimring; Mark R Looney
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.